^
    19h
    Identification of Prostate Cancer Specific Markers in Patients Compared to Healthy Participants (clinicaltrials.gov)
    P=N/A, N=60, Active, not recruiting, Tethis S.p.A. | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    23h
    Ablation of cancer cell secreted neuropeptide PTHLH/PTHrP provokes anti-tumor immunity in murine tongue squamous cell carcinoma. (PubMed, Sci Rep)
    Moreover, these tumors also showed lower expression of tumor proliferative and neuron markers. Together these findings established cancer cell secreted PTHLH as a critical mediator of immunosuppression and neuron infiltrations in HNSCC, particularly in tongue tumor.
    Preclinical • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • FOXP3 (Forkhead Box P3) • PTHLH (Parathyroid Hormone Like Hormone)
    |
    PD-L1 expression
    1d
    Combining Immunotherapy Salvage Surgery & IORT Tx Persistent/Recurrent Head & Neck Cancer (clinicaltrials.gov)
    P1, N=45, Recruiting, Ohio State University Comprehensive Cancer Center | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date • Tumor mutational burden • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab)
    1d
    Identification of Breast Cancer Specific Markers in Patients Compared to Healthy Participants (clinicaltrials.gov)
    P=N/A, N=84, Active, not recruiting, Tethis S.p.A. | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    1d
    Tannic acid-modified graphene oxide nanoplatform incorporating bortezomib as a combination chemo- and NIR-mediated photothermal oral cancer therapy. (PubMed, Colloids Surf B Biointerfaces)
    Moreover, in vivo studies in MOC2-induced tumor-bearing mice demonstrated a significant upregulation of ER stress markers, including PERK and PDI, as well as remodeling of macrophages, characterized by the upregulation of M1 markers, such as iNOS, TNF-α, and CD86. Thus, BTZ@GOT is an efficient nanotherapy that warrants further exploration for the treatment of oral carcinoma.
    Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha) • CD86 (CD86 Molecule)
    |
    bortezomib
    1d
    Comparative study on salivary IL- 8 and LDH among tobacco users without lesions, leukoplakia, oral submucous fibrosis and oral squamous cell carcinoma. (PubMed, Bioinformation)
    40 cases were analysed in this study. We show that salivary IL8 and LDH which can serve as one reliable biomarker in early detection of OSCC and a prognostic indicator for OPMDs.
    Journal
    |
    CXCL8 (Chemokine (C-X-C motif) ligand 8)
    1d
    Salvadora persica (Miswak) Extract as a Natural Therapeutic Agent for Oral Squamous Cell Carcinoma: in vitro and in silico Evaluation. (PubMed, Pak J Biol Sci)
    <b></b> The ethanolic extract of <i>Salvadora persica</i> demonstrates promising antioxidant, anti-inflammatory, anti-angiogenic and pro-apoptotic properties, indicating its potential as a natural therapeutic candidate for oral squamous cell carcinoma. These findings provide a strong foundation for further <i>in vivo</i> and preclinical studies to validate its efficacy and safety.
    Preclinical • Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha) • CASP3 (Caspase 3) • CASP7 (Caspase 7) • DAPK1 (Death Associated Protein Kinase 1)
    1d
    Pretreatment C-Reactive Protein/Albumin Ratio Can Predict Severity of Radiotherapy-Induced Oral Mucositis in Advanced Laryngeal Cancer Patients. (PubMed, Oral Dis)
    The pretreatment CAR value indicates clinical utility in predicting the likelihood of severe OM induced by RT-based therapy in patients with LC.
    Journal
    |
    CRP (C-reactive protein)
    2d
    A preliminary model of an oral dysplastic lesion on a chip. (PubMed, Tissue Cell)
    DOKs confined to the top channel showed slight and uneven E-cadherin and EpCAM (Epithelial Cell Adhesion Molecule) positivity, but evident positivity for Trop-2, confirming that their phenotype differed from that of healthy epithelial cells. The presented OD-OoC could enable in vitro monitoring of epithelial cell phenotype changes and cell migration across the membrane, suggesting its potential applicability in future oral cancer research.
    Journal
    |
    CDH1 (Cadherin 1) • CDH5 (Cadherin 5)
    2d
    FX-909-CLINPRO-1: A Study of FX-909 in Patients With Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma (clinicaltrials.gov)
    P1, N=120, Recruiting, Flare Therapeutics Inc. | N=75 --> 120 | Trial completion date: Jan 2027 --> Jan 2028 | Trial primary completion date: Sep 2026 --> Oct 2027
    Enrollment change • Trial completion date • Trial primary completion date • First-in-human
    |
    CD4 (CD4 Molecule) • PPARG (Peroxisome Proliferator Activated Receptor Gamma)
    |
    Keytruda (pembrolizumab) • FX-909
    3d
    IL-6 as a driver of bone invasion in IFIT2-depleted oral squamous cell carcinoma. (PubMed, Cancer Immunol Immunother)
    Notably, a high IL-6/IFIT2 ratio was associated with reduced median survival among OSCC patients. These findings indicate that IFIT2 depletion enhances OSCC-induced bone invasion predominantly through IL-6-mediated osteoclast activation, establishing the IL-6/IFIT2 axis as a critical regulator of OSCC progression and metastasis.
    Journal
    |
    IL6 (Interleukin 6) • IFIT2 (Interferon Induced Protein With Tetratricopeptide Repeats 2)
    3d
    Observational Study of Objective Response Rate to Ivonescimab Combined with Chemotherapy in Patients with Locally Advanced Resectable Oral and Oropharyngeal Squamous Cell Carcinoma (ChiCTR2600117410)
    P=N/A, N=20, Not yet recruiting, Zhujiang Hospital of Southern Medical University; Zhujiang Hospital of Southern Medical University
    New trial
    |
    Yidafan (ivonescimab)